US9850542B2

Gene signature to predict homologous recombination (HR) deficient cancer

University of Texas System

Abstract

Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: Chun-Jen Lin
Priority date: March 04, 2013
Filing date: March 04, 2014
Grant date: December 26, 2017
Publication date: December 26, 2017
Language: en
PDF source: https://patentimages.storage.googleapis.com/22/a3/17/72dda2a9645c6a/US9850542.pdf
Metadata fetched: August 29, 2026 00:24